Goldman Sachs keeps Buy rating for Chugai Pharmaceutical stock

Published on 10/21/2026 at 10:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chugai Pharmaceutical stock costs EUR 36.71 on October 21, 2026. The next report is scheduled for October 27, 2026 at 5:00 p.m. JST.

Ratings and upcoming results

Goldman Sachs maintained a Buy rating on October 20, 2026.
Chugai reported JPY 341.58 billion in second-quarter revenue for fiscal 2026.
Chugai Pharmaceutical stock traded at EUR 36.71 at 10:15 a.m. CEST at Lang & Schwarz on October 21, 2026.
Chugai's revised valuation target stood at JPY 11,000 on October 18, 2026.
Third-quarter results are scheduled for October 27, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) was quoted at EUR 36.71 at Lang & Schwarz on October 21, 2026 at 10:15 a.m. CEST. MarketWatch reported that Goldman Sachs maintained a Buy rating on October 20, 2026, keeping the latest analyst signal positive ahead of the company's next results.

Results set the next test

Chugai's investor-relations calendar schedules third-quarter results for fiscal 2026, covering January through September, on October 27, 2026 at 5:00 p.m. JST. The company also lists a results conference for 6:00 p.m. JST the same day, according to Chugai Pharmaceutical.

For context, Chugai reported JPY 341.58 billion in revenue and JPY 116.33 billion in net income for the second quarter of fiscal 2026, compared with JPY 290.01 billion and JPY 97.16 billion a year earlier. Those figures were reported by The Globe and Mail on October 8, 2026.

What does the target change mean?

Valuation remains a counterweight to the Buy rating. Simply Wall St said on October 18, 2026 that the referenced target fell from JPY 12,440 to JPY 11,000. The update linked the change to a lower assumed future price-to-earnings multiple, despite slightly higher revenue-growth and profit-margin assumptions.

Three dated developments

On July 24, 2026, Chugai reported second-quarter revenue of JPY 341.58 billion. On October 8, 2026, Citi maintained a Buy rating with a JPY 11,100 target, according to The Globe and Mail. On October 20, 2026, Goldman Sachs maintained its Buy rating, within a MarketWatch listing of 16 analyst ratings.

Dates for the calendar

The next two scheduled items are Chugai's third-quarter results on October 27, 2026 at 5:00 p.m. JST and the accompanying results conference at 6:00 p.m. JST, both listed by Chugai Pharmaceutical.

Stock and valuation context

Chugai's Japanese listing stood at JPY 6,511 at 3:30 p.m. JST on October 21, 2026. The same market context showed a JPY 5,974 to JPY 10,700 52-week range and market capitalization of JPY 10.7 trillion, placing the Japanese quote materially below its yearly high.

Chugai Pharmaceutical was trading at EUR 36.71 at Lang & Schwarz on October 21, 2026 at 10:15 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.